This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: B20.2 (HIV disease resulting in cytomegaloviral disease) | Special Copayment Reduction: V103 (serious illness related to HIV infection, 10% copayment for 5 years after registration) |
| B. Synonyms | HIV cytomegalovirus disease, HIV-CMV disease, HIV-CMV retinitis, HIV-associated cytomegalovirus infection, AIDS-related CMV disease |
| C. Adult onset | Likelihood of first onset in adulthood: very high — CMV disease occurs almost exclusively in adult HIV patients with severe immunosuppression (CD4 <50/μL), and the main affected group is adults (30s–60s) not receiving ART or with poor adherence. |
| 1. History | CMV discovered in the 1950s → surge of CMV opportunistic infections after AIDS was described in 1981 → CMV retinitis designated an AIDS-defining illness in 1983 → ganciclovir FDA-approved in 1989 → CMV disease decreased by 90% after ART in 1996 → temporary worsening possible after ART initiation due to IRIS. |
| 2. Causes | Human cytomegalovirus (Human CMV, HCMV, HHV-5). 70–80% of adults carry latent infection. Reactivation of latent virus at CD4 <50/μL. Involves the retina (most common), esophagus, colon, lung, and brain. |
| 3. Genetics | Host immune genes related to CMV susceptibility: TLR pathways, NK cell receptors (NKG2C polymorphism). CMV's own immune evasion genes such as UL16, UL18, and UL40. Ganciclovir resistance: UL97 (phosphotransferase, most common) and UL54 (DNA polymerase) mutations are clinically important. |
| 4. General epidemiology | Annual incidence of CMV retinitis in AIDS patients before ART was about 15–40% (CD4 <50/μL). Decreased by more than 90% after ART. Worldwide CMV seropositivity in the general adult population is 50–80%. CMV seropositivity in Korean adults is about 90% or higher. Still an important opportunistic infection in HIV patients non-adherent to ART. |
| 5. Pathophysiology | Latency after CMV primary infection (monocytes, endothelial cells, neurons) → CD4 T-cell depletion → loss of CMV-specific CD8+ CTLs → CMV reactivation → tissue destruction (cytopathic effect, apoptosis, immunopathology). CMV itself accelerates AIDS progression by trans-activating HIV replication. |
| 6. Symptoms | CMV retinitis: floaters, visual field defects, photopsia. CMV esophagitis: odynophagia, retrosternal pain. CMV colitis: abdominal pain, bloody stool, diarrhea. CMV pneumonia: dyspnea, dry cough, fever. CMV encephalitis: cognitive decline, altered consciousness. CMV polyneuropathy. |
| 7. Signs | CMV retinitis: fundus examination — "cottage cheese and ketchup" appearance (hemorrhage and exudate, perivascular inflammation). Plasma CMV DNA PCR (viral load). Endoscopy: CMV inclusion bodies of the esophagus and colon (Cowdry type A). MRI: CMV ventriculitis of the brain (periventricular enhancement). Tissue immunohistochemistry. |
| 8. Screening | Eye examination every 3–6 months (indirect ophthalmoscopy) for HIV patients with CD4 <50/μL. Retinitis may be present even without symptoms (asymptomatic retinitis). Plasma CMV DNA PCR is adjunctive for assessing disease risk. Monitor for anterior uveitis and vitritis due to IRIS after ART. |
| 9. Diagnosis | CMV retinitis: ophthalmic indirect ophthalmoscopy (gold standard). CMV gastrointestinal disease: endoscopy + biopsy (CMV inclusion bodies, immunohistochemistry). CMV pneumonia: BAL CMV culture and PCR + tissue findings. CMV encephalitis: CSF CMV PCR. Plasma CMV DNA PCR: adjunctive (limited specificity). Serology has no diagnostic value. |
| 10. Treatment | First line: ganciclovir IV 5 mg/kg twice daily × 2–3 weeks (induction), then valganciclovir 900 mg once daily (maintenance). Alternatives: foscarnet (for ganciclovir resistance), cidofovir. Retinitis: intravitreal ganciclovir implant is also possible. Start ART within 2 weeks. NSAIDs or steroids for IRIS management. |
| 11. Prognosis | Vision loss can be prevented with treatment of CMV retinitis, but if diagnosis is delayed, permanent visual impairment results. After ART, CMV maintenance therapy can be stopped if CD4 >100–150/μL is maintained. CMV encephalitis and pneumonia have a poor prognosis. Treatment is difficult if resistant CMV (UL97 mutation) develops. |
| 12. Prevention | Maintaining CD4 >100/μL with ART is the best prevention. Prophylactic valganciclovir (CD4 <50/μL) is considered in some guidelines, but is not routinely recommended at present because of induction of resistance and the effect of ART. Early detection through regular eye examinations. Education on the risk of CMV transmission through sexual contact and saliva. |
| 13. References | Jabs DA, Van Natta ML, Thorne JE, et al. Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Ophthalmology. 2004 … and 9 other papers |
Cytomegalovirus (CMV) was first isolated and cultured in the 1950s–60s, and its name derives from the cytopathic effect in which infected cells become markedly enlarged. In immunocompetent individuals, CMV primary infection causes a mononucleosis-like syndrome or passes asymptomatically, but in the 1960s–70s it was recognized that it causes serious organ involvement in immunocompromised patients (neonates, after organ transplantation, AIDS).
After the start of the HIV/AIDS epidemic in 1981, CMV retinitis emerged as one of the most common and fatal opportunistic complications in AIDS patients. In the pre-ART era, CMV retinitis occurred in about 15–40% of AIDS patients with CD4 <50/μL and, without appropriate treatment, led to blindness within months. In 1983 the CDC designated CMV retinitis an AIDS-defining illness. CMV esophagitis, colitis, pneumonia, and encephalitis were also important causes of morbidity and death in AIDS patients.
The treatment paradigm was formed when ganciclovir received FDA approval in 1989 for the treatment of AIDS-related CMV retinitis. Foscarnet (1991), cidofovir (1996), and oral valganciclovir (2001) were subsequently added. The introduction of highly active ART in 1996 brought a revolutionary change, reducing the occurrence of CMV disease by about 90%, but anterior uveitis and vitritis due to CMV-IRIS (immune reconstitution inflammatory syndrome) during immune recovery after ART initiation emerged as a new clinical challenge.
The causative pathogen of CMV disease is human cytomegalovirus (HCMV, or HHV-5). CMV is a double-stranded DNA virus belonging to the family Herpesviridae, subfamily Betaherpesvirinae, with a genome size of about 235 kb, the largest among human herpesviruses.
CMV serum antibodies are positive in 50–80% of the adult population; primary infection occurs in childhood through saliva, urine, sexual contact, blood transfusion, etc., and the virus then remains latent. Latent hosts are mainly monocytes/macrophages, hematopoietic progenitor cells, endothelial cells, and neurons.
In HIV/AIDS, CMV disease occurs mainly through reactivation of latent CMV. When CD4+ T cells (especially CMV-specific CD8+ cytotoxic T lymphocytes) are depleted by HIV, the immune surveillance that suppressed latent CMV is lost and the virus reactivates. CMV can involve almost any organ, but in HIV patients the most commonly involved organs are the retina (CMV retinitis), gastrointestinal tract (esophagitis, colitis), lungs, and central nervous system.
There is also evidence that CMV itself accelerates the progression of HIV infection. CMV immediate early (IE) gene products trans-activate the HIV LTR (long terminal repeat) to promote HIV replication, and CMV infection globally activates the immune system, creating an environment favorable to HIV replication.
As host genetic factors related to susceptibility to CMV disease, polymorphisms in innate immune pathways are attracting attention. Studies suggest that polymorphisms in Toll-like receptor (TLR) pathways, especially the TLR2, TLR4, and TLR9 genes, influence the outcome of CMV infection. Among NK cell receptors, copy number variation of the NKG2C (KLRC2) gene determines the degree of CMV-specific expansion of NK cells after CMV infection, and this is related to CMV control.
HLA type also influences the CMV immune response. There is a report that the HLA-B*35 genotype is associated with the risk of CMV retinitis in HIV patients. Because HLA class I molecules present for CMV-specific CD8+ T-cell responses, HLA type determines the efficiency of CMV-specific cellular immunity.
In terms of viral genetics, antiviral drug resistance is the most clinically important. Resistance to ganciclovir arises mainly from mutations in the UL97 gene (CMV phosphotransferase). UL97 catalyzes the first step of phosphorylating ganciclovir to ganciclovir monophosphate, so a UL97 mutation prevents activation of ganciclovir. High-dose ganciclovir resistance or broader resistance arises from mutations in the UL54 gene (CMV DNA polymerase), in which case cross-resistance to foscarnet may also develop. Antiviral resistance testing (UL97 and UL54 gene analysis) is used to decide on treatment changes.
CMV seroprevalence reaches 50–90% in the adult population and is reported to be about 90% or higher in Korean adults. This means that almost all HIV-positive adults are in a state of latent CMV infection.
In the pre-ART era (before 1996), the annual incidence of CMV retinitis in AIDS patients with CD4 <50/μL was about 15–40%, and it was the main cause of blindness in AIDS patients. CMV gastrointestinal disease (esophagitis, colitis) and CMV pneumonia also showed significant incidence in AIDS patients. After the introduction of ART, the incidence of CMV disease, including CMV retinitis, decreased by more than 90%.
However, CMV disease still occurs in patients who start ART late or have poor adherence and an extremely low CD4 count (CD4 <50/μL). In Korea as well, with late presenters (first HIV diagnosis at CD4 <200/μL or at the AIDS stage) accounting for about 20–30% of newly notified HIV cases, CMV disease remains clinically important.
CMV disease is also an important cause of morbidity in immunosuppressed patients after organ transplantation, but in that case an ICD code other than B20.2 is used. In the ART era, uveitis due to CMV-IRIS is a new clinical problem arising during immune recovery after ART initiation.
The pathogenesis of CMV disease is explained by two axes: reactivation of latent infection and loss of immune surveillance.
Mechanism of maintaining CMV latent infection: After primary infection, CMV is maintained in a latent state in cells of the monocyte/macrophage lineage, hematopoietic progenitor cells, and endothelial cells. In latency, expression of viral replication genes is suppressed and only latency-associated transcripts are expressed. In a healthy immune system, CMV-specific CD4+ and CD8+ T cells (accounting for about 10% or more of all T cells) monitor latent cells and suppress reactivation.
Loss of immune surveillance and reactivation: As HIV-induced CD4 T-cell depletion progresses, CMV-specific CD4+ T-cell helper function is lost, and CMV-specific CD8+ cytotoxic T lymphocytes (CTLs) also become dysfunctional and exhausted. When CMV-specific CTLs fall below a threshold at CD4 <50/μL, latent CMV reactivates, leading to hematogenous spread (CMV viremia) and tissue involvement.
Mechanism of tissue damage: CMV causes tissue damage through the cytopathic effect, which directly destroys infected cells, and through induction of apoptosis. In the retina, CMV destroys the retinal pigment epithelium and inner retinal neurons, causing retinal necrosis. Mucosal ulcers form in the gastrointestinal tract, interstitial pneumonia in the lungs, and periventricular necrosis in the brain.
CMV-IRIS: When CMV-specific T cells recover rapidly after ART initiation, an excessive immune response against previously undiagnosed sites of CMV infection (retina, anterior segment) may present as anterior uveitis or vitritis. This is understood as inflammation during immune recovery rather than worsening of the CMV disease itself.
CMV retinitis: the most common AIDS-related CMV disease, accounting for about 70–80% of all CMV disease. Initial symptoms are floaters in one eye, flashes of light like lightning in the visual field (photopsia), and peripheral visual field defects. If the macula is not involved, central vision is preserved early on. Without treatment, macular involvement within months leads to progressive loss of central vision and, ultimately, complete blindness.
CMV esophagitis: the main symptoms are odynophagia and retrosternal discomfort. Symptoms are similar to Candida esophagitis, but endoscopic findings differ in that CMV esophagitis forms a single or a few large confluent ulcers, whereas Candida esophagitis forms multiple small white plaques.
CMV colitis: bloody stool, mucoid diarrhea, abdominal pain, and fever occur. A subacute course progressing slowly over several weeks is characteristic. In severe cases, bowel perforation can occur.
CMV pneumonia: dyspnea, hypoxia, dry cough, and fever occur. Clinical features are similar to Pneumocystis pneumonia (PCP), so differentiation is necessary.
CMV encephalitis/ventriculitis: cognitive decline, altered consciousness, seizures, and focal neurologic deficits occur; this is the form of CMV disease with the poorest prognosis. CMV polyneuropathy is characterized by lower limb weakness and bladder and rectal dysfunction.
CMV retinitis: indirect ophthalmoscopy findings are the key to diagnosis. Characteristically, yellow-white confluent exudates (necrotizing retinal injury), described as "cottage cheese and catsup," and perivascular hemorrhage are seen. It shows a "brushfire" pattern, starting along the retinal vessels at the posterior pole and extending to the periphery. Vitreous haze is relatively slight (weak inflammatory response in the immunosuppressed state).
Plasma CMV DNA PCR: quantifies viral load, and detection of CMV DNA in patients with CD4 <100/μL suggests a risk of active CMV disease. However, false positives are possible (it can be detected in CMV-seropositive individuals even without viremia), and it cannot be used alone to diagnose CMV disease.
Endoscopic findings: in CMV esophagitis, a single or a few large shallow linear or oval ulcers (≥1 cm). In CMV colitis, mucosal hemorrhage, multiple ulcers, and mucosal sloughing. On tissue biopsy, Cowdry type A intranuclear inclusion bodies (giant intracellular "owl's eye" inclusions) are characteristic, and CMV antigen is confirmed by immunohistochemistry.
CMV encephalitis: MRI shows periventricular high signal intensity, ventricular enlargement, and periventricular enhancement. CSF CMV PCR is important for diagnosis.
Regular eye examinations for CMV retinitis in all HIV patients with CD4 <50/μL are a standard recommendation. In particular, asymptomatic CMV retinitis may progress without symptoms until it involves the macula or the area around the optic disc, so regular eye examinations are needed even in the absence of symptoms.
Eye examination schedule: immediate eye examination when CD4 <50/μL is diagnosed, then repeated at 3–6 month intervals. If the CD4 count rises to 100–150/μL or above after ART initiation, the risk of CMV retinitis falls markedly and the screening interval can be lengthened.
Regular monitoring of plasma CMV DNA PCR is recommended in some guidelines, but because its positive predictive value is not perfect, it is not used alone to diagnose CMV disease or to decide on prophylactic dosing. In patients with CD4 <50/μL who develop abdominal symptoms (diarrhea, bloody stool) or odynophagia, differential diagnosis including endoscopy is performed immediately. When there is cognitive decline or altered consciousness, brain MRI and CSF examination are needed to differentiate CMV encephalitis.
Diagnosis of CMV retinitis: indirect ophthalmoscopy by an ophthalmologist is the gold standard. Clinical diagnosis is possible with typical retinal findings. In atypical cases, fluorescein angiography (FFA) and optical coherence tomography (OCT) are used adjunctively.
CMV gastrointestinal disease: upper endoscopy (esophagitis) or colonoscopy (colitis) + biopsy is key. Histology is characterized by giant cells ("owl's eye") with Cowdry type A intranuclear inclusions and intracytoplasmic inclusions, and CMV antigen is confirmed by immunohistochemistry (CMV monoclonal antibody).
CMV pneumonia: CMV culture and CMV PCR of bronchoalveolar lavage (BAL) specimens, and histologic confirmation of CMV through tissue biopsy (video-assisted thoracoscopic surgery or transbronchial biopsy). BAL CMV isolation alone is insufficient for confirmation (asymptomatic shedding is possible), and histologic findings are needed.
CMV encephalitis: CSF CMV PCR is the key diagnostic test (sensitivity ~80%, specificity ~90% or higher). Brain MRI (periventricular enhancement). CSF findings: pleocytosis with mononuclear cells, elevated protein, normal or decreased glucose.
Ganciclovir/valganciclovir: first-line treatment for CMV disease. Induction therapy: ganciclovir 5 mg/kg IV twice daily × 2–3 weeks, or valganciclovir 900 mg orally twice daily (equivalent in effect to ganciclovir in retinitis). Maintenance therapy: valganciclovir 900 mg orally once daily. Bone marrow suppression (neutropenia, thrombocytopenia) is the main adverse effect, so regular complete blood count monitoring is needed.
Foscarnet: an alternative for ganciclovir-resistant CMV (UL97 mutation) or ganciclovir adverse effects. Serious adverse effects include nephrotoxicity (renal function monitoring essential), electrolyte abnormalities (hypocalcemia, hypomagnesemia), and seizures. Induction: 60 mg/kg IV three times daily or 90 mg/kg twice daily × 2–3 weeks. Maintenance: 90–120 mg/kg IV once daily.
Cidofovir: used for ganciclovir-resistant CMV; IV dosing every 2 weeks is convenient, but nephrotoxicity is severe. Probenecid pretreatment and adequate hydration are essential.
Letermovir: a CMV UL56 (terminase complex) inhibitor, a new drug approved for CMV prophylaxis after transplantation. Its role in treating CMV in HIV patients is still being established.
ART optimization: starting or optimizing ART immediately together with treatment of CMV disease to promote CD4 recovery is essential for improving long-term prognosis.
Stopping CMV maintenance therapy: maintenance therapy can be stopped when, after ART initiation, the CD4 count is stably maintained at 100–150/μL or above for 3–6 months or longer and CMV retinitis is inactive. Regular eye examinations continue after stopping.
The prognosis of CMV disease varies greatly depending on the organ involved and the timing of diagnosis.
CMV retinitis: vision loss can be prevented by early detection and prompt treatment. However, if diagnosis is delayed or central macular involvement has already progressed, permanent visual impairment remains. CD4 recovery through ART is the most important prognostic factor suppressing recurrence of CMV retinitis. Anterior uveitis due to CMV-IRIS can mostly be controlled with appropriate treatment (NSAIDs, topical steroids).
CMV gastrointestinal disease: mostly improves with appropriate antiviral treatment and ART. If bowel perforation occurs in CMV colitis, surgical management is needed and mortality increases.
CMV encephalitis/ventriculitis: the form with the poorest prognosis; even with treatment, most patients are left with severe neurological damage and mortality is high. The CD4 count is very low (usually <10/μL), and patients often die before immune recovery is sufficient even after ART is started.
Antiviral-resistant CMV (UL97 mutation, ganciclovir resistance) can arise during long-term ganciclovir treatment; in this case a switch to foscarnet is needed, but treatment becomes more difficult because of the adverse effects of foscarnet.
Maintaining the CD4 count with ART: the most effective way to prevent CMV disease. Keeping the CD4 count at 100/μL or above, ideally 200/μL or above, markedly lowers the risk of CMV reactivation.
Ganciclovir/valganciclovir prophylaxis: some earlier guidelines recommended oral ganciclovir/valganciclovir prophylaxis against CMV in HIV patients with CD4 <50/μL, but because of the effectiveness of ART and the bone marrow suppression and risk of inducing resistance with prophylactic antivirals, the current US AIDSinfo guidelines do not recommend routine prophylaxis. Instead, a strategy of early detection through regular eye examinations is taken.
Regular eye examinations: in HIV patients with CD4 <50/μL, eye examinations every 3–6 months are essential for early detection of asymptomatic CMV retinitis.
Prevention of CMV transmission: because CMV is transmitted through saliva, urine, sexual secretions, blood transfusion, etc., condom use is recommended for CMV-negative HIV patients during sexual intercourse with a CMV-positive partner. For transfusions, transfusion-related CMV infection is prevented by using CMV-negative or leukoreduced blood products.
Jabs DA, Van Natta ML, Thorne JE, et al. Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: 2. Second eye involvement and retinal detachment. Ophthalmology. 2004;111(12):2232-2239. DOI: 10.1016/j.ophtha.2004.06.013. PMID: 15582080.
Jabs DA. Cytomegalovirus retinitis and the acquired immunodeficiency syndrome — bench to bedside: LXVII Edward Jackson Memorial Lecture. Am J Ophthalmol. 2011;151(2):198-216. DOI: 10.1016/j.ajo.2010.10.018. PMID: 21055534.
Pertel PE, Hirschtick RE. Cytomegalovirus. In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 9th ed. Elsevier; 2020:1986-2002.
Drew WL. Cytomegalovirus resistance testing: pitfalls and problems for the clinician. Clin Infect Dis. 2010;50(5):733-736. DOI: 10.1086/650536. PMID: 20113174.
Bowen EF, Griffiths PD, Davey CC, et al. Lessons from the natural history of cytomegalovirus. AIDS. 1996;10 Suppl 1:S37-S41. PMID: 8871429.
Karavellas MP, Lowder CY, Macdonald JC, et al. Immune recovery vitritis associated with inactive cytomegalovirus retinitis: a new syndrome. Arch Ophthalmol. 1998;116(2):169-175. DOI: 10.1001/archopht.116.2.169. PMID: 9488266.
Mellouli M, Ben Aicha H, Zili J, et al. CMV retinitis in HIV: review of the current situation. J Virol. 2022;96(10):e0028922. DOI: 10.1128/jvi.00289-22. PMID: 35522089.
Polis MA, de Smet MD, Baird BF, et al. Increased survival of a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis who received sodium phosphonoformate (foscarnet). Am J Med. 1993;94(2):175-180. DOI: 10.1016/0002-9343(93)90183-t. PMID: 8430714.
Jacobson MA, Mills J. Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Clinical findings, diagnosis, and treatment. Ann Intern Med. 1988;108(4):585-594. DOI: 10.7326/0003-4819-108-4-585. PMID: 2831952.
Korean Society for AIDS; Korean Society of Infectious Diseases. Korean Guidelines for Diagnosis and Treatment of HIV/AIDS. Infect Chemother. 2021;53(4):e54. DOI: 10.3947/ic.2021.0091. PMID: 34910839.